OBJECTIVES: Stereotactic body radiotherapy (SBRT) is a novel form of noninvasive, highly conformal radiation treatment that delivers a high dose to tumor. The advantage of the technique resides in its ability to provide a high dose to tumor but spare normal tissues to an extent not previously possible. In this paper we will provide an introduction and review of this technology with regard to its use in gynecologic malignancies. Preliminary results from our experience are presented for the purpose of illustrating the range of SBRT applications in gynecologic oncology. METHODS: A comprehensive literature review was conducted and our experience from the past three years was reviewed. RESULTS: Six case series are published that report results of SBRT for gynecologic malignancies. Sixteen gynecologic patients have been treated with SBRT at our institution. Treatment sites include pelvic and periaortic nodes (9 patients), oligometastatic disease (2), and cervical or endometrial primary tumors when other conventional external radiation or brachytherapy techniques were unsuitable (5). Preliminary follow-up at a median of 11 months (range, 0.3-33 months) demonstrates 79% locoregional control, 43% distant failure, and 50% overall survival. CONCLUSIONS: SBRT boosts to macroscopic periaortic node recurrences and other sites seem to provide local control and a possibility of long-term disease-free survival in carefully selected patients. Previously this had been difficult to achieve with conventional radiotherapy because of the proximity of periaortic nodes to small bowel. SBRT also offers a novel approach for minimally invasive treatment in the management of gynecological cancer where current surgical and radiotherapy techniques are unsuitable.
OBJECTIVES: Stereotactic body radiotherapy (SBRT) is a novel form of noninvasive, highly conformal radiation treatment that delivers a high dose to tumor. The advantage of the technique resides in its ability to provide a high dose to tumor but spare normal tissues to an extent not previously possible. In this paper we will provide an introduction and review of this technology with regard to its use in gynecologic malignancies. Preliminary results from our experience are presented for the purpose of illustrating the range of SBRT applications in gynecologic oncology. METHODS: A comprehensive literature review was conducted and our experience from the past three years was reviewed. RESULTS: Six case series are published that report results of SBRT for gynecologic malignancies. Sixteen gynecologic patients have been treated with SBRT at our institution. Treatment sites include pelvic and periaortic nodes (9 patients), oligometastatic disease (2), and cervical or endometrial primary tumors when other conventional external radiation or brachytherapy techniques were unsuitable (5). Preliminary follow-up at a median of 11 months (range, 0.3-33 months) demonstrates 79% locoregional control, 43% distant failure, and 50% overall survival. CONCLUSIONS: SBRT boosts to macroscopic periaortic node recurrences and other sites seem to provide local control and a possibility of long-term disease-free survival in carefully selected patients. Previously this had been difficult to achieve with conventional radiotherapy because of the proximity of periaortic nodes to small bowel. SBRT also offers a novel approach for minimally invasive treatment in the management of gynecological cancer where current surgical and radiotherapy techniques are unsuitable.
Authors: Kelsey L Corrigan; Alison Yoder; Brian De; Lilie Lin; Anuja Jhingran; Melissa M Joyner; Patricia J Eifel; Lauren E Colbert; Karen H Lu; Ann H Klopp Journal: Gynecol Oncol Date: 2021-12-30 Impact factor: 5.304
Authors: Charles A Kunos; Tracy M Sherertz; Mazen Mislmani; Rodney J Ellis; Simon S Lo; Steven E Waggoner; Kristine M Zanotti; Karin Herrmann; Robert L Debernardo Journal: Front Oncol Date: 2015-06-05 Impact factor: 6.244
Authors: Charles A Kunos; James Brindle; Steven Waggoner; Kristine Zanotti; Kimberly Resnick; Nancy Fusco; Ramon Adams; Robert Debernardo Journal: Front Oncol Date: 2012-12-05 Impact factor: 6.244